GlobeNewsWire
17 Aug 2026, 12:45 UTC · 2h ago
NTHI's Nasdaq Advantage Takes on New Meaning After Its Breakthrough Phase 2a Results
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
GlobeNewsWire
17 Aug 2026, 12:45 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
NeOnc Technologies' NEO100 Phase 2a results for recurrent IDH1-mutant high-grade glioma showed a six-month progression-free survival rate of 48.9%, significantly exceeding the 20% historical benchmark. — Positive Phase 2a clinical data is a primary value driver for biotech companies, drastically reducing binary risk and increasing the probability of regulatory success.
+0.80The company reported a median overall survival of approximately 26.1 months for NEO100 with no major toxicities noted. — Strong survival data and a clean safety profile enhance the drug's competitive positioning and attractiveness for future partnerships.
+0.60NeOnc has an at-the-market (ATM) program allowing it to sell up to $75 million of common stock to fund further development. — While providing a necessary funding mechanism for growth, ATM programs create potential downward pressure on share prices due to dilution.
+0.30Continue reading
6 related stories
Top 1 mover · tap to explore
Which stocks this story touches
The company reported breakthrough Phase 2a results for NEO100 that substantially exceeded historical benchmarks.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
MarketBeat
10h ago
